News Releases Keyword Search Year None20242023202220212020 Date Title 04/04/24 Optinose to Present at the Needham Virtual Healthcare Conference 03/15/24 XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps 03/07/24 Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights 02/29/24 Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results 01/18/24 Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice